Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127168951 | 12716895 | 1 | I | 20160520 | 20160825 | 20160906 | 20160906 | EXP | FR-PFIZER INC-2016403601 | PFIZER | 18.00 | MON | M | Y | 9.60000 | KG | 20160906 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127168951 | 12716895 | 1 | PS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous (not otherwise specified) | 0.5 MG, 1X/DAY (CYCLE 2) | .5 | MG | 71484 | .5 | MG | QD | |||||
| 127168951 | 12716895 | 2 | SS | IFOSFAMIDE EG | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 1 G, 1X/DAY (CYCLE 2) | 3 | G | 0 | 1 | G | QD | |||||
| 127168951 | 12716895 | 3 | SS | DOXORUBICINE TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 7 MG, 1X/DAY (CYCLE 2) | 21 | MG | 0 | 7 | MG | QD | |||||
| 127168951 | 12716895 | 4 | SS | ETOPOPHOS | ETOPOSIDE PHOSPHATE | 1 | Intravenous (not otherwise specified) | 50 MG, 1X/DAY (CYCLE 2) | 150 | MG | 0 | 50 | MG | QD | |||||
| 127168951 | 12716895 | 5 | C | SODIUM BICARBONATE. | SODIUM BICARBONATE | 1 | UNK | 0 | |||||||||||
| 127168951 | 12716895 | 6 | C | FUNGIZONE | AMPHOTERICIN B | 1 | UNK | 0 | |||||||||||
| 127168951 | 12716895 | 7 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | UNK | 0 | |||||||||||
| 127168951 | 12716895 | 8 | C | UVESTEROL VITAMINE A D E C | 2 | UNK | 0 | ORAL SOLUTION | |||||||||||
| 127168951 | 12716895 | 9 | C | ZOPHREN /00955301/ | ONDANSETRON | 1 | UNK | 0 | |||||||||||
| 127168951 | 12716895 | 10 | C | DOLIPRANE | ACETAMINOPHEN | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127168951 | 12716895 | 1 | Ewing's sarcoma |
| 127168951 | 12716895 | 2 | Ewing's sarcoma |
| 127168951 | 12716895 | 3 | Ewing's sarcoma |
| 127168951 | 12716895 | 4 | Ewing's sarcoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127168951 | 12716895 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127168951 | 12716895 | Febrile bone marrow aplasia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127168951 | 12716895 | 1 | 20160511 | 20160511 | 0 | |
| 127168951 | 12716895 | 2 | 20160511 | 20160513 | 0 | |
| 127168951 | 12716895 | 3 | 20160511 | 20160513 | 0 | |
| 127168951 | 12716895 | 4 | 20160511 | 20160513 | 0 |